Walter Willoughby, MD
Pulmonary Disease · Las Vegas, NVNPI 1376592477
Payments from drug & device makers
Across 519 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$1K
- Boehringer Ingelheim$1K
- Mylan Specialty L.p.$832
- Amgen$823
- Regeneron Healthcare Solutions, Inc.$532
- plus $2K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 108 | $3,213 |
| GSK | 68 | $1,212 |
| Boehringer Ingelheim | 76 | $1,033 |
| Mylan Specialty L.p. | 49 | $832 |
| Amgen | 50 | $823 |
| Regeneron Healthcare Solutions, Inc. | 24 | $532 |
| Genentech USA, Inc. | 39 | $394 |
| Sanofi | 20 | $381 |
| Axsome Therapeutics, Inc. | 14 | $259 |
| Philips North America LLC | 7 | $197 |
| Grifols USA, LLC | 10 | $191 |
| Insmed, Inc. | 7 | $141 |
| Paratek Pharmaceuticals, Inc. | 6 | $122 |
| Circassia Inc. | 9 | $117 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Jazz Pharmaceuticals Inc. | 5 | $77 |
| Verona Pharma, Inc. | 3 | $66 |
| Actelion Pharmaceuticals US, Inc. | 3 | $60 |
| Electromed, Inc. | 5 | $49 |
| Pfizer | 1 | $33 |
| Merck | 1 | $33 |
| Harmony Biosciences LLC | 1 | $33 |
| Inogen, Inc. | 2 | $27 |
| Baxter Healthcare | 2 | $26 |
| United Therapeutics Corporation | 1 | $25 |
| Resmed Corp | 1 | $21 |
| Liquidia Technologies, Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $20 |
| Pulmonx Corporation | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
| Itamar Medical Inc | 1 | $17 |
How this compares
$10,112 in reported general payments places this provider in the 75th percentile of 84 pulmonary disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Las Vegas
- Naresh SinghLas Vegas$711K
- Arthur RomeroLas Vegas$327K
- Lloyd DelmundoLas Vegas$150K
- Jonathan BaktariLas Vegas$89K
- Abhishek KumarLas Vegas$85K
- Jerome HruskaLas Vegas$72K
- Vishisht MehtaLas Vegas$38K
- Kamran KhanLas Vegas$17K
- John WojcikLas Vegas$14K
- Paul StewartLas Vegas$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.